BURLINGTON, Mass., June 8, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the foundation U.S. patent application for CNDO-109, licensed by Coronado Biosciences from the University College London Business PLC, for its Natural Killer (NK) cell therapy program. The patent, U.S. Patent Application No. 11/856,466, is entitled, "Method for activating natural killer cells by tumor cell preparation in vitro" and has a current expiration date of July 2027.
